The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

In recent years, chemotherapy-induced cardiovascular disease has emerged as a significant cause of mortality among cancer ...

In view of the patient's long progression-free survival (12.9 months), we decided to resume intramuscular octreotide (30 mg every 3 weeks) with capecitabine and liposomal doxorubicin chemotherapy ...

Pegylated liposomal doxorubicin (Doxil ®) is the only approved, routinely used nanocarrier formulation for EOC. It may be considered a viable first-line alternative to paclitaxel in standard ...

or investigator’s choice chemotherapy (pegylated liposomal doxorubicin, paclitaxel, topotecan, or gemcitabine). The primary endpoint was overall survival (OS). Findings from the pre-specified ...

a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma ...

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) saw a significant drop in short interest in March. As of March ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.